Short Interest in Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) Grows By 360.0%

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI) was the target of a large growth in short interest in April. As of April 15th, there was short interest totalling 2,300 shares, a growth of 360.0% from the March 31st total of 500 shares. Based on an average trading volume of 4,600 shares, the short-interest ratio is presently 0.5 days.

Inhibitor Therapeutics Price Performance

INTI stock remained flat at $0.09 during mid-day trading on Friday. The company has a market capitalization of $14.76 million, a P/E ratio of -8.58 and a beta of -0.84. The business’s fifty day moving average is $0.07 and its 200 day moving average is $0.08. Inhibitor Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.30.

Inhibitor Therapeutics (OTCMKTS:INTI) last issued its earnings results on Friday, March 29th. The company reported ($0.01) EPS for the quarter.

About Inhibitor Therapeutics

Inhibitor Therapeutics, Inc, a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.